Since the expression of dihydropyrimidine dehydrogenase (DPD) is known to be lower in female colorectal cancer patients (19), it appears more likely that women might be more sensitive to 5-FU and its prodrug capecitabine (19). The gene discussed is DPYD; the disease is colorectal cancer.